GSA Capital Partners LLP Has $771,000 Stock Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Key Points

• GSA Capital Partners LLP significantly increased its holdings in Ironwood Pharmaceuticals by 3,683.6%, acquiring a total of 524,676 shares worth approximately $771,000.
• Ironwood Pharmaceuticals reported a loss of $0.14 per share for the recent quarter, missing analyst expectations, and generated $41.14 million in revenue, falling short of the anticipated $67.02 million.
• Several analysts downgraded the company's stock ratings, with target prices reduced to as low as $1.00, resulting in a consensus rating of "Hold" and an average price target of $4.78.

GSA Capital Partners LLP increased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 3,683.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 524,676 shares of the biotechnology company's stock after purchasing an additional 510,809 shares during the quarter. GSA Capital Partners LLP owned approximately 0.32% of Ironwood Pharmaceuticals worth $771,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Federated Hermes Inc. increased its stake in shares of Ironwood Pharmaceuticals by 252.3% during the first quarter. Federated Hermes Inc. now owns 1,305,362 shares of the biotechnology company's stock worth $1,919,000 after purchasing an additional 934,886 shares during the period. KLP Kapitalforvaltning AS increased its stake in shares of Ironwood Pharmaceuticals by 719.8% during the first quarter. KLP Kapitalforvaltning AS now owns 198,400 shares of the biotechnology company's stock worth $292,000 after purchasing an additional 174,200 shares during the period. Y Intercept Hong Kong Ltd increased its stake in shares of Ironwood Pharmaceuticals by 162.6% during the first quarter. Y Intercept Hong Kong Ltd now owns 39,782 shares of the biotechnology company's stock worth $58,000 after purchasing an additional 24,635 shares during the period. Allianz Asset Management GmbH grew its position in shares of Ironwood Pharmaceuticals by 411.5% during the 1st quarter. Allianz Asset Management GmbH now owns 293,100 shares of the biotechnology company's stock worth $431,000 after purchasing an additional 235,800 shares in the last quarter. Finally, CWM LLC increased its holdings in shares of Ironwood Pharmaceuticals by 801.1% during the first quarter. CWM LLC now owns 57,001 shares of the biotechnology company's stock worth $84,000 after purchasing an additional 50,675 shares during the period.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ IRWD traded up $0.04 during trading hours on Tuesday, hitting $0.79. 454,494 shares of the stock were exchanged, compared to its average volume of 2,937,572. The company has a market cap of $127.35 million, a PE ratio of -3.94 and a beta of 0.33. The company's fifty day simple moving average is $0.72 and its two-hundred day simple moving average is $1.23. Ironwood Pharmaceuticals, Inc. has a 1-year low of $0.53 and a 1-year high of $6.28.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative return on equity of 1.87% and a negative net margin of 9.89%. The firm had revenue of $41.14 million for the quarter, compared to analyst estimates of $67.02 million. As a group, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on IRWD shares. Leerink Partners lowered their target price on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a report on Monday, April 14th. Jefferies Financial Group reaffirmed a "hold" rating and set a $0.70 target price (down from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Craig Hallum cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th. Citizens Jmp cut shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday, April 14th. Finally, Wall Street Zen raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Ironwood Pharmaceuticals has an average rating of "Hold" and a consensus target price of $4.78.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.